{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00987",
      "entity_text" : "LTE 4",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01016",
      "entity_text" : "Omalizumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Omalizumab lowered the urinary concentration of LTE 4 and PGD 2 in patients with AERD and decreased asthma exacerbations and hospitalizations [XREF_BIBR].",
  "reading_complete" : "2020-08-03T10:15:45Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T10:08:54Z",
  "trigger" : "lowered",
  "evidence" : [ "Omalizumab lowered the urinary concentration of LTE 4" ],
  "pmc_id" : "5951071",
  "score" : 0
}